Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05814458

The Efficiency of Transcranial Direct Current Stimulation in the Treatment of Anorexia Nervosa

The main goal of the study (a 3-week, randomized, double-blind, and placebo-controlled study) is to determine the effect of Transcranial Direct Current Stimulation (tDCS) on the mental state and advances in nutritional rehabilitation in patients with AN. The primary hypothesis assumes that tDCS will reduce the symptoms of depression, improve cognition functions and it will have a positive effect on the reduction of restriction related to body weight and diet.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

10 year–30 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Ist Department of Psychiatry, Psychotherapy and Early Intervention

Lublin, Lublin Voivodeship, 20-439, Poland

About this study

The aim of the study is to assess the effect of tDCS stimulation on psychological and biological factors in patient suffering for AN with particular attention to the safety of such additional therapy. Transcranial direct current stimulation (tDCS) is a non-invasive and currently considered safe method of neurostimulation. It is based on the use of direct current of very low intensity, up to 2000uA-2mA, and supplying it to the brain through electrodes placed on the scalp. In this way, the polarity of the cell membranes of neurons is induced, and this influences changes in the cortical excitation of the brain.

Results confirming the efficacy of such a therapeutic approach would provide support for the introduction of brain stimulations as a valuable part of treatment in psychiatric wards but also as a part of home-based treatment.

The protocol was developed by a multidisciplinary researcher team of a psychiatrist, psychologist, psychotherapist and nutritionists. Thanks to this, it is possible to evaluate the progress taking place in various fields.

To the best of our knowledge, this will be the first intervention study assessing the efficacy of tDCS in AN taking into account not only psychological tests, but also biochemical markers (including levels of neurotrophins) or the electrical activity of the brain.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed written Informed Consent Form,
  • Patients aged 10-30 years old,
  • Meet the DSM-5 criteria for AN,
  • Body mass index (BMI) ≤ 17,5 kg/m2,
  • A willingness and motivation to follow the study protocol.

Exclusion criteria

  • Not giving Informed, Written Consent
  • Diagnosis of neurological diseases, as epilepsy;
  • Contraindications to tDCS, ie. pacemakers, metal parts around the head;
  • Psychiatric comorbidities (except specific personality disorder) including mental retardation, organic brain dysfunction, or addiction (except nicotine and caffeine);
  • Pregnancy or pregnancy planning;
  • Changes in psychopharmacotherapy during hospitalization

Treatment and study plan

tDCS

Device

Patients will be receiving twice a day tDCS (applied current at 2mA) stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.

PLACEBO

Device

Patients will be receiving twice a day sham stimulation, for 3 weeks on working days (30 sessions in total) and each stimulation will last 25 minutes. The anode will be located on the left, while the cathode- on the right dorsolateral prefrontal area of scalp. The commercially available Soterix 1x1 tDCS mini-CT LTE device (model 1601-LTE) will be used for stimulation.

Primary outcomes

  1. Change in severity of eating disorder symptoms 1

    Time frame: The test will be performed four times: Before stimulation, baseline (V1), immediately after stimulation (V2) two weeks after the intervention (V3), and two months after the intervention (V4)

    The severity of symptoms will be assessed with Eating Attitudes Test (EAT-26)

  2. Change in severity of eating disorder symptoms 2

    Time frame: The test will be performed three times: Before stimulation, baseline (V1), immediately after stimulation (V2) and two weeks after the intervention (V3)

    The severity of symptoms will be assessed with Eating Disorder Examination Questionnaire (EDE-Q 6.0).

  3. Change in eating habits and opinions about food and nutrition

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and two weeks after intervention (V3)

    To evaluate changes in eating habits and opinions about food and nutrition the Questionnaire of Eating Behaviours (QEB) will be used. It is a qualitative questionnaire designed to study eating habits and opinions about food and nutrition. The first part of the questionnaire covers the frequency of consumption of selected products, the frequency of eating meals and their typical composition. In the second part of the questionnaire, there are 26 statements about food and nutrition, which enable the assessment of the level of nutritional knowledge of the respondents.

  4. Change in food intake variety

    Time frame: The test will be performed three times: Before stimulation, baseline (V1), immediately after stimulation (V2) and two weeks after the intervention (V3)

    Food Intake Variety will be assessed with The Variety Food Consumption Questionnaire. It is a qualitative food consumption frequency questionnaire. It is a simple tool to collect information on the consumption of (yes / no) 63 assortment groups of products.

  5. Change in assessment of stress levels

    Time frame: The test will be performed four times: Before stimulation, baseline (V1), immediately after stimulation (V2) two weeks after the intervention (V3), and two months after the intervention (V4)

    The severity of stress will be assessed with Perceived Stress Scale (PSS-10). This test consists 10 questions and is used to measure stress based on subjective feelings related to problems and personal events, behavior, coping with stress.

  6. Change in severity of depressive symptoms 1

    Time frame: The tests will be performed twice: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    Severity of depressive symptoms will be assessed with Beck's Depression Inventory (BDI)

  7. Change in severity of depressive symptoms 2

    Time frame: The tests will be performed three times: Before stimulation, baseline (V1), immediately after stimulation (V2), and two months after the intervention (V4)

    Severity of depressive symptoms will be assessed with Questionnaire for the Diagnosis of Depression in Children and Adolescents (CDI2).

  8. Change in meta-cognition

    Time frame: The test will be performed three times: Before stimulation, baseline (V1), immediately after stimulation (V2), and two months after the intervention (V4)

    To assess metacognitive abilities Meta-Cognition Questionnaire (MCQ-A) will be used. Reliable and valid instrument for measuring meta-cognitive beliefs in adolescents (12-18 lat). The MCQ-A assesses the severity of dysfunctional meta-cognitive beliefs in adolescents (12-18) that affect their daily functioning. The first and second subscales measures "positive and negative beliefs about worry," Subscale 3 measures "cognitive confidence," Subscale 4 measures "beliefs about superstition, punishment and responsibility". Finally, subscale 5 measures "cognitive self-consciousness,".

  9. Change in attention and perceptiveness

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To assess levels of attention Color connection test (CTT-1, CTT-2) and Test of attention and perceptiveness will be used.

  10. Change in intensity of intrusive thoughts

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To assess intensity of intrusive thoughts CY-BOCS scale will be used

  11. Change in intensity of rumination

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To assess intensity of rumination the Ruminance-Reflectivity Questionnaire will be used

  12. Change in visual memory

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To assess visual memory test BENTON will be used. This test is used to test memory, visual perception and graphomotor skills. The examined person draws the presented patterns (10 pieces) from memory or redraws them, depending on the version and methods of the research carried out by the researcher.

  13. Change in body image self-esteem

    Time frame: The test will be performed three times: Before stimulation, baseline (V1), immediately after stimulation (V2) and two weeks after the intervention (V3)

    To assess body image self-esteem Appearance Self-Rating Sheet (ASRS) will be used. Assessment of 25 dimensions related to your body - (different parts of your body). The patient receives a visualization of the body figure on the drawing and evaluates its individual elements. The test allows you to assess the importance of appearance for patients, the assessment of satisfaction with one's appearance and the satisfaction index. The SES self-assessment questionnaire will also be used

  14. Change in cognitive abilities 1

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To assess cognitive abilities Matching Familiar Figures Test (MFF)

  15. Change in cognitive abilities 2

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To assess cognitive abilities Verbal Fluency Test will be used.

  16. Change in self-esteem

    Time frame: The test will be performed three times: Before stimulation, baseline (V1), immediately after stimulation (V2) and two weeks after the intervention (V3)

    The Rosenberg Self-Esteem Scale (SES) will be used. SES is a tool for assessing the level of general self-esteem - a relatively stable disposition understood as a conscious attitude (positive or negative) towards the Self

  17. Change in emotion regulation

    Time frame: The test will be performed three times: at baseline (V1), immediately after stimulation (V2), and 2 months after stimulation (V4).

    A shortened 16-item version of a questionnaire designed for the rapid assessment of difficulties in emotion regulation Difficulties in Emotion Regulation Scale DERS-16 wil be performed. The scale measures five domains, such as lack of emotional acceptance, impulsivity, and difficulties with goal-directed behavior, using a 5-point scale.

  18. Change in autistic traits

    Time frame: The test will be administered three times: at baseline (V1), immediately after stimulation (V2), and 2 months after stimulation (V4).

    The Autism Spectrum Quotient (AQ) is a self-administered questionnaire used to measure the degree to which a person shows autistic traits.

  19. Change in mental states

    Time frame: The test will be administered three times: at baseline (V1), immediately after stimulation (V2), and 2 months after stimulation (V4).

    The questionnaire Mentalization Scale (MentS) is used for a rapid assessment of the capacity to reflect on mental states (emotions, intentions, and beliefs).

  20. Change in body-related conversations

    Time frame: The test will be peformed three times: at baseline (V1), immediately after stimulation (V2), and 2 months after stimulation (V4).

    Family Talk Questionnaire Fat Talk refers to negative, body-related conversations between girls or young women.

  21. Change in cognitive functions

    Time frame: The test will be performed twice: at baseline (V1), immediately after stimulation (V2)

    A neuropsychological diagnostic tool Rey-Osterrieth Complex Figure used to assess visuospatial abilities, visual memory, and executive functions (planning and organization).

  22. Change in anxiety level

    Time frame: The test will be performed three times: at baseline (V1), immediately after stimulation (V2), and 2 months after stimulation (V4).

    The STAI (State-Trait Anxiety Inventory) is a psychological tool used to measure anxiety as both a state (a temporary feeling of tension) and a trait (a stable personality disposition). It consists of two subscales (X-1 and X-2, or Y-1 and Y-2), each containing 20 questions, with scores ranging from 20 to 80 points.

Secondary outcomes

  1. Change in electrolyte levels

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate electrolyte levels (mmol/l) in blood serum following tests will be performed:

    sodium, phosphorus, magnesium, calcium, potasium

  2. Change in morphotic elements 1

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate morphotic elements complete morphology with smear will be performed:

    RBC - Red Blood Cell (M/µl)

  3. Change in morphotic elements 2

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate morphotic elements complete morphology with smear will be performed:

    Hemoglobin (mmol/l) Mean Corpuscular Hemoglobin Concentration (mmol/l)

  4. Change in morphotic elements 3

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate morphotic elements complete morphology with smear will be performed:

    Hematocrit

  5. Change in morphotic elements 4

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate morphotic elements complete morphology with smear will be performed:

    Mean Corpuscular Volume (fl)

  6. Change in morphotic elements 5

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate morphotic elements complete morphology with smear will be performed:

    Mean Corpuscular Hemoglobin (pg)

  7. Change in morphotic elements 6

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate morphotic elements complete morphology with smear will be performed:

    Ferritin ( ng/ml)

  8. Change in morphotic elements 7

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate morphotic elements complete morphology with smear will be performed:

    White Blood Cell (K/µl) Lymphocytes (K/µl)

  9. Change in morphotic elements 8

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate morphotic elements complete morphology with smear will be performed:

    Monocytes (G/l)

  10. Metabolic changes 1

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate metabolic changes in blood serum Thyroid parameters will be examined: FT3 (pmol/l), FT4 (pmol/l)

  11. Metabolic changes 2

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate metabolic changes in blood serum the pituitary gland parameter will be examined: TSH (µIU/ml)

  12. Neurophysiologic changes 1

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate neurophysiologic changes EEG (theta and alpha wave power) test will be performed

  13. Change in neurotrophin levels

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate neurotrophin levels in blood serum tests will be performed: BDNF (pg/ml), Neurotrphin 3 and 4 (pg/ml), NGF (pg/ml)

  14. Change in food intake regulators:

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate food intake regulators in blood serum tests will be performed: leptin (pg/ml), visfatin (pg/ml)

  15. Body composition changes 1

    Time frame: The test will be performed four times: Before stimulation, baseline (V1), immediately after stimulation (V2), two weeks after the intervention (V3), and two months after the intervention (V4)

    To evaluate body composition changes BIA body composition analysis will be performed: Body weight (kg)

  16. Body composition changes 2

    Time frame: The test will be performed four times: Before stimulation, baseline (V1), immediately after stimulation (V2), two weeks after the intervention (V3), and two months after the intervention (V4)

    To evaluate body composition changes BIA body composition analysis will be performed: Intracellular and extracellular water (l/%)

  17. Body composition changes 3

    Time frame: The test will be performed four times: Before stimulation, baseline (V1), immediately after stimulation (V2), two weeks after the intervention (V3), and two months after the intervention (V4)

    To evaluate body composition changes BIA body composition analysis will be performed: Lean body mass (kg/%)

  18. Body composition changes 4

    Time frame: The test will be performed four times: Before stimulation, baseline (V1), immediately after stimulation (V2), two weeks after the intervention (V3), and two months after the intervention (V4)

    To evaluate body composition changes BIA body composition analysis will be performed: Fat mass (kg/%)

  19. Changes in HPA axis biomarker

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate HPA axis cortisol (nmol/l) in blood serum will be tested

  20. Metabolic changes 3

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate metabolic changes in blood serum Total Protein parameter will be examined.

  21. Metabolic changes 4

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate metabolic changes in blood serum the glucosis level will be performed.

  22. Cardiac Parameter Changes

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate changes in cardiac parameters in blood serum, NT-proBNP will be measured (pg/mL).

  23. Metabolic changes 5

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate metabolic changes in blood serum, a lipid profile parameter will be measured: total cholesterol (mg/dL)

  24. Metabolic changes 6

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2).

    To evaluate metabolic changes in blood serum, a lipid profile parameter will be measured: LDL cholesterol (mg/dL).

  25. Metabolic changes 7

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2).

    To evaluate metabolic changes in blood serum, a lipid profile parameter will be measured: triglycerides (mg/dL).

  26. Metabolic changes 8

    Time frame: The test will be performed two times: Before stimulation, baseline (V1) and immediately after stimulation (V2)

    To evaluate metabolic changes in blood serum, a lipid profile parameter will be measured: non-HDL cholesterol (mg/dL).

Sponsors and collaborators

Lead sponsor

Medical University of Lublin

Other

Registry information

Official study title

The Efficiency of Transcranial Direct Current Stimulation in the Treatment of Anorexia Nervosa - a Randomised, Double-blind Clinical Trial

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Apr 14, 2023
Registry last updated
Feb 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.